<code id='2A92461329'></code><style id='2A92461329'></style>
    • <acronym id='2A92461329'></acronym>
      <center id='2A92461329'><center id='2A92461329'><tfoot id='2A92461329'></tfoot></center><abbr id='2A92461329'><dir id='2A92461329'><tfoot id='2A92461329'></tfoot><noframes id='2A92461329'>

    • <optgroup id='2A92461329'><strike id='2A92461329'><sup id='2A92461329'></sup></strike><code id='2A92461329'></code></optgroup>
        1. <b id='2A92461329'><label id='2A92461329'><select id='2A92461329'><dt id='2A92461329'><span id='2A92461329'></span></dt></select></label></b><u id='2A92461329'></u>
          <i id='2A92461329'><strike id='2A92461329'><tt id='2A92461329'><pre id='2A92461329'></pre></tt></strike></i>

          knowledge

          knowledge

          author:comprehensive    Page View:2475
          close-up of psoriasis on a hand. -- biotech coverage from STAT
          A close-up of psoriasis on a hand. Adobe

          San Francisco startup Alumis Inc. has raised $259 million in a bid to best big pharma’s work in plaque psoriasis.

          Alumis announced its Series C round Wednesday and plans to move its lead drug into Phase 3 trials. Venture firm Foresite Capital, which incubated Alumis, co-led the financing with Samsara BioCapital and venBio Partners.

          advertisement

          Alumis’ lead drug, ESK-001, is an oral medicine designed to help patients with the most common type of psoriasis by inhibiting a signaling protein called TYK2. Research has shown that the TYK2 protein plays a role in diseases where the immune system overreacts, which has made it a popular drug target in recent years.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          DIEP, the 'gold standard' of breast reconstruction, is under threat
          DIEP, the 'gold standard' of breast reconstruction, is under threat

          AdobeIn1983,Iflewhomefromcollegetobewithmymotherasshewokeupfromamastectomy.Sheoptedoutofbreastrecons

          read more
          Why failed clinical trials don’t always spell doom for a new drug
          Why failed clinical trials don’t always spell doom for a new drug

          AdobeThisarticlewasadaptedfromSTAT’slatestreport,“Failedtrial,successfuldrug:howanegativereadoutcans

          read more
          Heart attack and stroke risk calculators need revising
          Heart attack and stroke risk calculators need revising

          AdobeForbusyprimarycarephysicianslikeme,anannualphysicalwitha27-year-oldmaleisablessing.Sincewe’real

          read more

          Amylyx's ALS drug launch starts strong. It could be trouble for FDA

          MollyFerguson/STATBehindthestellarcommerciallaunchofAmylyxPharmaceuticals’treatmentforALSliesanuncom